Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Highlights From Viking Global’s Investor Letter: Alibaba Group Holding Ltd (BABA), Regeneron Pharmaceuticals Inc (REGN)

Page 1 of 2

We have seen a copy of Viking Global’s third quarter investor letter. Andreas Halvorsen’s Viking Global is among the most successful long/short equity hedge funds (Stock Picks, Investor Letters). Its flagship hedge fund returned 4.1% during the third quarter, bringing its gains to 10.8% for the first 9 months of the year. Below you can read their discussion about three of their big position.

Viking Global had the biggest position in Alibaba Group Holding Ltd (NYSE:BABA) among the 700+ hedge funds we are tracking. Billionaires Dan Loeb (see his portfolio), George Soros, and Rob Citrone were also among the top 5 Alibaba Group Holding Ltd (NYSE:BABA) shareholders at the end of the third quarter. Here is what Halversen said about Alibaba in his investor letter:

Andread Halvorsen Viking Global Investor Letter

“Our biggest winner for VGE was Alibaba, contributing 2.0%. When we made our initial investment in 2012, we were intrigued by the company’s dominant position in Chinese eCommerece because we believed that this rapidly expanding market would enjoy long-term secular growth. In addition, we were excited by the company’s advertising-based  revenue model and the potential for further monetization and margin expansion. Although the stock price has appreciated materially since we acquired our original investment, we remain bullish on the prospects of Alibaba, which ranked as our sixth largest position on September 30.”

Obviously Viking Global is a very large fund with its hands in a lot of pies. Biotech stock Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of them.

“VLF’s best-performing long was Regeneron Pharmaceuticals, a large-cap biotechnology company. It has one of the most innovative R&D organizations and richest clinical development pipelines in the sector. Its most important revenue driver is Eylea, a treatment for retinal disorders such as wet age-related macular degeneration (a leading cause of severe vision loss in people over the age of 60). In June, Regeneron’s share price underperformed due to concerns that physicians were shifting prescriptions away from Eylea towards less costly alternatives. When our own due diligence, including extensive checks with retinal specialists, gave us confidence that such concerns were unfounded, we increased our stake in the company. The stock recovered sharply advancements in the company’s early-stage drug pipeline.”

The third stock that we will bring to your attention is another healthcare stock.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!